Enhe Biotechnology
恩和生物
Enhe Biotechnology (恩和生物, also known as Bota Bio or Bota Biosciences) is a global synthetic biology company founded by Cheryl Cui (崔好), who serves as its CEO . The company operates at industrial scale in synthetic biology, with approximately 200 employees as of early 2024, and formally launched its commercialization process in 2023 . In July 2021, it raised over $100 million in Series B funding led by Sequoia China (红杉中国), with follow-on participation from investors including 5Y Capital, Matrix Partners China, Sherpa Healthcare Partners, Source Code Capital, and Meituan . The company was recognized in 2023 as one of China's high-growth innovative companies by China Entrepreneur magazine .
AI-generated — may contain errors, please verify.
Coverage
The beginning of a miracle often lies within the thing itself | 5Y News Monthly
The big news from last month.
五源资本·Success is rarely replicable; what matters is finding your own path | 5Y View x Bota Bio x METiS Pharmaceuticals
Cross-disciplinary methodology for entrepreneurship.
五源资本·September, Sprinting on the Cloud | 5Y News Monthly
The big news from last month.
五源资本·As Fierce as August | 5Y News Monthly
The big news from last month.
五源资本·5Y News | Synthetic Biology Company Bota Bio Raises Over $100 Million to Accelerate Efficient Design and Scaled Production of Bio-based Products
5Y Capital continues to pay close attention to emerging technologies at the intersection of information science and life sciences.
五源资本·
